Nanotechnology Drug Delivery Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 8.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Nanotechnology Drug Delivery Market Analysis
The nanotechnology drug delivery market is poised to grow at a CAGR of 8.3% over the forecast period.
During the covid-19 pandemic, most pharmaceutical companies and governments were attempting to provide effective medical treatment to covid-19 patients, and medication delivery systems were expected to play an important role in this context. The use of nanoparticles for the treatment of COVID-19 increased. The use of drug delivery devices and systems increased, as nanoparticle drug formulations play a vital role in pulmonary drug delivery. The article published in November 2021, titled 'Nanoparticles as an effective drug delivery system in COVID-19', stated that nanomedicines and nano drug delivery systems and devices show effectiveness against COVID-19 as treatments. The ongoing research on the effectiveness of nanotechnology drug delivery in the treatment of COVID-19 boosted the market and drove the growth of the market studied, during the pandemic.
The rising prevalence of chronic diseases and illnesses such as diabetes, cancer, and cardiovascular disease has increased the demand for innovative medications with targeted delivery for various chronic diseases. The prevalence of diabetes among the global population is drastically increasing. According to the data published by the International Diabetes Federation (IDF) Diabetes Atlas Tenth Edition 2021, in the year 2021, approximately 537 million adults (aged 20-79 years) were living with diabetes. The same source estimated that the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. The rising burden of diabetes is likely to increase the demand for more technically advanced drug delivery options for treatment and diagnosis. Additionally, according to the Global Cancer Observatory (Globocan) Statistics 2020, there are 19.3 million new cases of cancer all over the world, accounting for both sexes in 2020. The same source reports that the incidence of cancer is growing at a rapid pace in the world and estimates that the number of new cases of cancer in both sexes will reach 28.8 million by 2040. Hence, the rising prevalence of chronic diseases creates demand for nanotechnology drug delivery systems, thereby boosting market growth.
Moreover, increasing advancements in nanoscale technologies and research and development activities have also supported the growth of the market. For instance, in July 2022, the EU Horizon 2020 B-SMART project attempted to create a novel method of delivering RNA through the blood-cerebrospinal fluid barrier, allowing treatments to be delivered directly to the brain. A therapy like this has the potential to enhance the lives of millions of people who suffer from neurodegenerative diseases. Hence, such advancements in nano drug delivery systems propel the growth of the market.
However, the cost of nanotechnology drug delivery medicine and stringent regulations for the mechanism approval have restrained the growth of the market.
Nanotechnology Drug Delivery Market Trends
This section covers the major market trends shaping the Nanotechnology Drug Delivery Market according to our research experts:
Oncology Segment is Expected to be the Major Contributor to the Market Over the Forecast Period
Cancer is a chronic disease and one of the leading causes of death in the world. Cancer is a disease, in which there will be a rapid creation of abnormal cells that grow beyond their usual boundaries. According to the Globocan 2020 fact sheet, an estimated 19,292,789 new cancer cases were diagnosed worldwide. Additionally, according to estimates from the International Agency for Research on Cancer (IARC), by 2040, the global burden of cancers is expected to grow to 28.8 million new cancer cases. This increasing prevalence of cancer creates the demand for chemotherapy, which require a better drug delivery system, driving the segment for drug delivery devices over the forecast period.
According to the study published in February 2022, titled "Nanoparticle-based drug delivery systems in cancer: A focus on inflammatory pathways" Nanoparticles (NPS) are a type of medication carrier that is typically less than 100 nm in size and can target tumor locations while minimizing off-target effects. Furthermore, NPs can stimulate innate and adaptive immune systems in the tumor microenvironment (TME), inducing a cancer-fighting immune response. Surprisingly, targeting cancer cells with NPs aids in the elimination of treatment resistance and tumor recurrence, as well as the prevention of inflammation. Thus, the effectiveness of the nanoparticles in cancer treatment is expected to rise in demand nanotechnology drug delivery market.
Furthermore, developments in nanoscale technologies and research and development activities have aided market expansion. For instance, in July 2022, biomarkers found by MIT researchers indicate whether distinct types of cancer cells would took up specific nanoparticles. The researchers discovered dozens of biological features that determine whether cancer cells take up different types of nanoparticles after studying interactions between 35 different types of nanoparticles and roughly 500 distinct types of cancer cells. The findings could help researchers better customise drug-delivery particles to certain forms of cancer, or build novel particles that capitalise on the biological characteristics of specific types of cancer cells. Thus, growing number of research activities with respect to segment, likely to boost the segment growth.
Thus, owing to the abovementioned factors, the market segment is expected to project lucrative growth over the forecast period.
North America is Expected to Dominate the Nanotechnology Drug Delivery Market Over the Forecast Period
The North American nanotechnology drug delivery market is estimated to grow significantly during the study period owing to rising incidences of chronic diseases like cancer and HIV, increasing product launches, and rising initiatives by key market players.
According to Statistics published by the Centre for Disease Control and Prevention updated in May 2022, in the United States, there are 30,635 newly diagnosed cases of HIV in 2020 and out of which 24,488 are males and 5,450 are females. The same source also reported that people aged 13-34 years account for nearly 57% of newly diagnosed cases of HIV. Such a high HIV incidence in the country creates an increasing demand for nanotechnology drug delivery devices, and thus drives the growth of the market.
Additionally, according to the estimates of the GLOBOCAN in 2020, there would be 22,81,658 new cancer cases diagnosed in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer. Thus, the growing prevalence of chronic diseases is expected to rise in demand for advanced and targeted therapy which is likely to support the market expansion over the forecast period.
Moreover, growing technological advances in the nanotechnology-based drug delivery system are likely to boost the market growth. For instance, in January 2022, the Case Western Reserve University researchers created nanoparticles that transport clot-promoting enzymes to the bleeding site and then release them there to produce fibrin - the body's mesh-like component vital to stopping the bleeding - where it is needed.
Thus, all aforementioned factors are expected to boost the market growth in the region.
Nanotechnology Drug Delivery Industry Overview
The nanotechnology drug delivery market is moderately competitive. The increasing number of companies found investing in research and development in this field is allowing for a rise in R&D activities, helping the market expand at a steady pace. There are also collaborations among leading pharmaceutical companies and technology developers that have picked pace in the market in the past few years. Several companies are also focusing on the development of nanomedicines for the treatment of a variety of cancers. Some of the major players are Taiwan Liposome Company, Nanobiotix, Aquanova AG, NanoCarrier Co Ltd, and NanOlogy LLC
Nanotechnology Drug Delivery Market Leaders
-
Taiwan Liposome Company
-
Nanobiotix
-
Aquanova AG
-
NanoCarrier Co Ltd
-
NanOlogy LLC
*Disclaimer: Major Players sorted in no particular order
Nanotechnology Drug Delivery Market News
- In June 2022, Baker Heart and Diabetes Institute researchers designed and developed a unique nanoparticle drug delivery technology that can identify and treat various diseases as well as greatly improve the efficacy of a medicine used to treat atherosclerosis.
- In August 2022, Researchers from Cytimmune Sciences, a clinical-stage biotech company, presented new data on the company's novel cancer nanomedicines. The presentation took place at the Cytokine Drug Development Conference held in Boston, Massachusetts
Nanotechnology Drug Delivery Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Prevalence of Cancer and Genetic and Cardiovascular Diseases
4.2.2 Increasing Advancements in Nanoscale Technologies
4.2.3 Growing Preference for Personalized Medicines
4.3 Market Restraints
4.3.1 High Cost of Nanotechnology Drug Delivery Technique
4.3.2 Stringent Regulations for Commercial Introduction
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Technology
5.1.1 Nanocrystals
5.1.2 Nanoparticles
5.1.3 Liposomes
5.1.4 Micelles
5.1.5 Others
5.2 By Application
5.2.1 Neurology
5.2.2 Oncology
5.2.3 Cardiovascular/Physiology
5.2.4 Anti-inflammatory/Immunology
5.2.5 Anti-infective
5.2.6 Other Applications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AbbVie Inc
6.1.2 Aquanova AG
6.1.3 BlueWillow Biologics
6.1.4 Bristol Myers Squibb (Celgene Inc)
6.1.5 CYTIMMUNE SCIENCES INC
6.1.6 Nanobiotix
6.1.7 NanoCarrier Co Ltd
6.1.8 NanOlogy LLC
6.1.9 Taiwan Liposome Co
6.1.10 Merck KGaA
6.1.11 Aphios Corporation
6.1.12 Concept Medical Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Nanotechnology Drug Delivery Industry Segmentation
As per the scope of the report, nanotechnology drug delivery applications occur through the use of designed nanomaterials as well as forming delivery systems from nanoscale molecules. These materials help in improving the bioavailability of the drug. Nanotechnology drug delivery is widely used in the health care industry in applications such as neurology, anti-infective, cardiovascular disorders, and others. The Nanotechnology Drug Delivery Market is segmented by Technology (Nanocrystals, Nanoparticles, Liposomes, Micelles, Others), Application (Neurology, Oncology, Cardiovascular/Physiology, Anti-inflammatory/Immunology, Anti-infective, Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Technology | |
| Nanocrystals | |
| Nanoparticles | |
| Liposomes | |
| Micelles | |
| Others |
| By Application | |
| Neurology | |
| Oncology | |
| Cardiovascular/Physiology | |
| Anti-inflammatory/Immunology | |
| Anti-infective | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Nanotechnology Drug Delivery Market Research FAQs
What is the current Global Nanotechnology Drug Delivery Market size?
The Global Nanotechnology Drug Delivery Market is projected to register a CAGR of 8.30% during the forecast period (2024-2029)
Who are the key players in Global Nanotechnology Drug Delivery Market?
Taiwan Liposome Company, Nanobiotix, Aquanova AG, NanoCarrier Co Ltd and NanOlogy LLC are the major companies operating in the Global Nanotechnology Drug Delivery Market.
Which is the fastest growing region in Global Nanotechnology Drug Delivery Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Nanotechnology Drug Delivery Market?
In 2024, the North America accounts for the largest market share in Global Nanotechnology Drug Delivery Market.
What years does this Global Nanotechnology Drug Delivery Market cover?
The report covers the Global Nanotechnology Drug Delivery Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Nanotechnology Drug Delivery Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Nanotechnology Drug Delivery Industry Report
Statistics for the 2024 Nanotechnology Drug Delivery market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Nanotechnology Drug Delivery analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
